

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



邁博藥業
Mabpharm Limited
迈博药业有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2181)

VOLUNTARY ANNOUNCEMENT
EXCLUSIVE PROMOTION SERVICE AGREEMENT WITH KEXING
BIOPHARM REGARDING CMAB008 (INFLIXIMAB)
IN MAINLAND CHINA

This announcement is made by Mabpharm Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on March 30, 2022, Taizhou Mabtech Pharmaceutical Limited* (泰州邁博太科藥業有限公司) (“**Taizhou Pharmaceutical**”), an indirect wholly-owned subsidiary of the Company, entered into an exclusive promotion service agreement (the “**Agreement**”) with Kexing Biopharm Co., Ltd.* (科興生物製藥股份有限公司) (“**Kexing Biopharm**”), a company listed on the Science and Technology Innovation Board of Shanghai Stock Exchange (stock code: 688136), pursuant to which Taizhou Pharmaceutical granted an exclusive licence to promote CMAB008類停® in mainland China (excluding Hong Kong, Macau and Taiwan regions) (“**Promotion Service Area**”) to Kexing Biopharm. Taizhou Pharmaceutical will receive partnership milestone payments and commercial milestone payments for this exclusive promotion license, and is expected to generate substantial revenue from ongoing sales in the future. The parties have agreed in the Agreement on the target sales volume and if the sales volume of the drug does not meet the target, Taizhou Pharmaceutical has the right to terminate the contract or continue to perform the contract after being compensated by Kexing Biopharm in accordance with the Agreement. Taizhou Pharmaceutical will continue to possess all the rights and interests in respect of CMAB008類停® in the Promotion Service Area other than promotion right.

The Company’s product pipeline covers drugs in immunology, allergy, oncology, gastroenterology and other fields. The Company’s sales strategy will be more focused on the sales of relevant drugs in advantageous fields, and it will actively cooperate with companies with rich experience and long-established resources to expedite the introduction of marketing resources and achieve a rapid increase in market share, so as to leverage economies of scale and scaling effect through cooperation. Entering into the Agreement will be conducive to enhancing the brand influence of CMAB008類停® and provide exponential momentum for rapid growth of sales of the Company’s products.

ABOUT CMAB008 類停®

CMAB008類停® (infliximab): It was approved for marketing by the National Medical Products Administration of the People's Republic of China in July 2021 (Guo Yao Zhun Zi S20210025) for the treatment of 1) ulcerative colitis in adults; 2) ankylosing spondylitis; 3) rheumatoid arthritis; 4) Crohn's disease in adults and pediatric patients aged above 6 years old; 5) fistula Crohn's disease; and 6) psoriasis. The antibody drug production base of Taizhou Pharmaceutical in China Medical City, Taizhou, Jiangsu Province also successfully passed the compliance inspection of Good Manufacturing Practice (GMP) for CMAB008類停® by Jiangsu Provincial Drug Administration. According to the regulations of China's basic medical insurance program (the "Medical Insurance"), CMAB008類停® has also been automatically included in the Medical Insurance, and has obtained the Medical Insurance registration code from the National Healthcare Security Administration. CMAB008類停® is approved for the treatment of six indications which have huge long-term unmet market demand, with more than 10 million patients with such indications in the PRC and the number of patients is still growing. According to MENET (米內網), half-year sales of imported infliximab in Chinese public hospitals were RMB550 million in the first half of 2021, up 105% year-on-year.

ABOUT KEXING BIOPHARM

Kexing Biopharm is an integrated innovative biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein therapeutics and microbiota agents, focusing on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunological, hematological, digestive and degenerative diseases. Kexing Biopharm has a strong market terminal coverage, with a nationwide sales network covering over 18,000 terminals in hospitals of all levels, basic medical institutions and pharmacies, including over 6,500 hospitals. Kexing Biopharm is well established and various products rank among the top in terms of market share in China.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately market CMAB008 類停® successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Mabpharm Limited
Jiao Shuge
Chairman

Hong Kong, March 31, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wang Hao, Mr. Tao Jing, Mr. Li Yunfeng, and Dr. Li Jing as executive Directors; Mr. Jiao Shuge and Mr. Guo Jianjun as non-executive Directors; and Mr. Guo Liangzhong, Dr. Zhang Yanyun and Dr. Liu Linqing as independent non-executive Directors.

* For identification purpose only